{
    "nct_id": "NCT04359784",
    "official_title": "Phase 2 Pilot Study to Evaluate Efficacy and Safety of Anakinra to Prevent CD19-Targeted CAR-T Cell-Related Cytokine Release Syndrome (CRS) and Neurotoxicity in Patients With B Cell Lymphoma",
    "inclusion_criteria": "* Subjects must be 18 years of age or older\n* Karnofsky performance status of >= 60%\n* Patients with B-cell non-Hodgkin lymphoma (B-NHL) and eligible for treatment with liso-cel. Patients treated with non-conforming (out-of-specification) liso-cell may remain on study.\n* Negative serum pregnancy test within 2 weeks of enrollment for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year\n* Fertile male and female subjects must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last dose of anakinra\n* Ability to understand and provide informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent). Pulsed corticosteroid use for disease control is acceptable\n* Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the principal investigator (PI)\n* Known hypersensitivity to Escherichia â‚¬ coli-derived proteins, anakinra, or to any component of the product\n* Major organ dysfunction defined as:\n\n  * Serum creatinine > 2.5 mg/dL\n  * Significant hepatic dysfunction (Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 5x upper limit of normal; bilirubin > 3.0 mg/dL) unless due to malignancy or Gilbert's syndrome in the opinion of the PI or designee\n  * Subjects with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing. Those with a forced expiratory volume in 1 second (FEV1) of < 50% of predicted or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% will be excluded\n  * Significant cardiovascular abnormalities as defined by any one of the following: New York Heart Association (NYHA) class III or IV congestive heart failure, clinically significant hypotension, uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of < 35%\n* Uncontrolled serious and active infection",
    "miscellaneous_criteria": ""
}